Acadia Pharma (ACAD) reported Q2 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $134.6 million versus the consensus estimate of $130.43 million.
GUIDANCE:
Acadia Pharma sees FY2022 revenue of $510-540 million, versus the consensus of $531 million.